RAN and hepatocellular carcinoma: We further evaluated the anti-tumor activity of Tb7, Tc1, Tc3, and Tc4 against SK-Hep1 and PLC-PRF5 cells, confirming that Tc3 had the highest potency (IC50 = 1.64 and 1.79 μM, respectively) for hepatic carcinoma (Figure 2A).